Angiogenesis, angiogenic factor expression and prognosis of gastric carcinoma

Anticancer Research

Volumn 21, Issue 6 B, 2001, Pages 4365-4372

  Saito, Hiroaki ^a   Tsujitani, Shunichi ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Basic fibloblast growth factor; Gastric carcinoma; Interleukin 8; p53; Thrombospondin; Thymidine phosphorylase; TNP 450; Transforming growth factor 1; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOSTATIN; BASIC FIBROBLAST GROWTH FACTOR; EFLORNITHINE; FUMAGILLOL CHLOROACETYLCARBAMATE; INTERLEUKIN 8; PROTEIN P53; SEMAXANIB; THROMBOSPONDIN; THYMIDINE PHOSPHORYLASE; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

CANCER IMMUNOTHERAPY; CLINICAL TRIAL; GENE THERAPY; HUMAN; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; STOMACH CARCINOMA; TUMOR GROWTH;

ANGIOGENESIS INDUCING AGENTS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; STOMACH NEOPLASMS;

EID: 0035574310     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (123)

1. Tumor angiogenesis
2. Angiogenesis in cancer, vascular, rheumatoid and other disease
3. Signaling vascular morphogenesis and maintenance
4. Mechanisms of angiogenesis
5. Tumor angiogenesis as a predictor of recurrence in gastric carcinoma
6. Association of turnout vasculature with tumour progression and overall survival of patients with non-early gastric carcinomas
7. Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinomas
8. Quantification of angiogenesis in solid tumors: An international consensus on the methodology and criteria of evaluation
9. Tumor angiogenesis and metastasis: Correlation in invasive breast carcinoma
10. Relation of neovascularization to metastasis of non-small cell lung cancer
11. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma
12. Demonstration and characterization of the angiogenic properties of cervical dysplasia
13. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis and proliferation of human colon cancer
14. Neoangiogenesis and relation to nuclear p53 accumulation and vascular endothelial growth factor (VEGF) expression in advanced gastric carcinoma
15. Pathological characteristics of gastric cancer that develop hematogenous recurrence, with special reference to the site of recurrence
16. Tumor angiogenesis: A new significant and independent prognostic indicator in early stage breast carcinoma
17. Spontaneous apoptosis is inversely related to intratumoral microvessel density in gastric carcinoma
18. Life, death and the pursuit of apoptosis
19. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors
20. Molecular controls of apoptosis: Differentiation/growth arrest primary response genes, proto-oncogene and tumor suppressor genes as positive and negative modulators
21. Angiostatin induces and sustains dormancy of human primary tumors in mice
22. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
23. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth
24. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes Memorial Award Lecture
25. What is the evidence that tumors are angiogenesis-dependent?
26. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma
27. The expression of vascular endothelial growth factor (VEGF) correlates with hematogenous recurrence in gastric carcinoma
28. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer
29. Isolation and characterization of vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells
30. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
31. Vascular endothelial growth factor is a secreted angiogenic mitogen
32. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression
33. Association of vascular endothelial growth factor expression with tumor angiogenesis and early response in primary breast cancer
34. Prognostic significance of vascular endothelial growth factor in node-negative breast carcinoma
35. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma
36. Vascular endothelial growth factor expression in early stage ovarian carcinoma
37. The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA
38. Serum concentrations of vascular endothelial growth factor and nitrite as an estimate of in vivo nitric oxide in patients with gastric cancer
39. Concentrations of vascular endothelial growth factor in the sera of gastric cancer patients
40. Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma
41. Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activity
42. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor
43. Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma
44. Thymidine phosphorylase expression in gastric cancer in association with proliferative activity and angiogenesis
45. Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer
46. The expression of thymidine phosphorylase and its correlation with angiogenesis in gastric adenocarcinoma
47. Enzymatic formation of 5-fluorouracil from 1-(tetrahydro-2-furanyl)-5-fluorouracil (Tegafur) in human tumor tissues
48. Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumor tissues
49. The expression of thymidine phosphorylase correlated with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma
50. Molecular and biological characterization of fibroblast growth factor, an angiogenic factor which also controls the proliferation and differentiation of mesoderm and neuroectoderm derived cells
51. Structural characterization and biological function of fibroblast growth factor
52. Fibroblast growth factor: Structural and biological properties
53. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth
54. Transforming growth factor-β: Recent progress and new challenges
55. Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer
56. Immunocytochemically detectable TGF beta is associated with malignancy in thyroid epithelial neoplasia
57. Transforming growth factor beta and transforming growth factor beta receptor expression in human meningioma cells
58. Enhanced expression of transforming growth factor β isoforms in pancreatic cancer correlates with decreased survival
59. Differential localization of transforming growth factor-β isoforms in human gastric mucosa and overexpression in gastric carcinoma
60. Immunohistochemical study of epidermal growth factor and transforming growth factor-β in the penetrating type of early gastric cancer
61. Immonoelectron microscopic localization of transforming growth factor beta 1 and latent transforming growth factor beta 1 binding protein in human gastrointestinal carcinomas: Qualitative differences between cancer and stromal cells
62. Transforming growth factor beta 1 induces apoptosis cell death in cultured human gastric carcinoma cells
63. Transforming growth factor beta: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro
64. Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro
65. Vascular endothelial growth factor is induced in response to transforming growth factor β in fibroblastic and epithelial cells
66. The expression of transforming growth factor-β1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma
67. Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin-1 and tumor necrosis factor
68. Interleukin-8 and MCAF: Novel leukocyte recruitment and activity cytokines
69. Interleukin-8 as a macrophage-derived mediator of angiogenesis
70. Interleukin-8: A corneal factor that induces neovascularization
71. Induction of haptotactic migration of melanoma cells by neutrophil activating protein/IL-8
72. Effect of IL-8 on epidermal proliferation
73. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor
74. Role of C-X-C chemokines as regulators of angiogenesis in lung cancer
75. Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma
76. Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice
77. Constitutive production of multiple cytokines and a human chorionic gonadotrophin β-subunit by a human bladder cancer cell line (KU-19-19): Possible demonstration of totipotential differentiation
78. Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique
79. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice
80. Expression of interleukin-8 correlates with vascularity in human gastric carcinomas
81. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin
82. Thrombospondin exerts an anti-angiogenic effect on cord formation by endothelial cells in vitro
83. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential and angiogenesis
84. Cultured human fibroblasts synthesize and secrete thrombospondin and incorporate it into extracellular matrix
85. Platelet-derived growth factor and heparin-like glycosaminoglycans regulate thrombospondin synthesis and deposition in the matrix by smooth muscle cells
86. Monocytes and macrophages synthesize and secrete thrombospondin
87. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines
88. Thrombospondin: Structure and regulation of expression
89. Thrombospondin's
90. COMP (cartilage oligomeric matrix protein) is structurally related to the thrombospondin
91. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene
92. Inhibition of angiogenesis by thrombospondin-2
93. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity
94. Thrombospondin-1 expression in bladder cancer: Association with P53 alterations, tumor angiogenesis and tumor progression
95. Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1
96. Thrombospondin 2 gene expression is correlated with decreased vascularity in non-small cell lung cancer
97. The p53 protooncogene can act as a suppressor of transformation
98. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene
99. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
100. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression
101. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity
102. Neoangiogenesis and p53 protein in lung cancer: Their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression
103. Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis
104. Suppression of tumor metastasis by angiogenesis inhibition
105. The treatment of amebiasis with fumagillin
106. Potent anti-angiogenic action of AGM-1470: Comparison to the fumagillin parent
107. Prevention of hepatic metastasis of human colon cancer by angiogenesis inhibitor TNP-470
108. Angiogenesis inhibitor TNP-470 (AGM-1470) potentially inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines
109. Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo
110. Inhibition of angiogenesis and growth of human nerve-sheath tumors by AGM-1470
111. Effect of angiogenesis inhibitor TNP-470 on the progression of human gastric cancer xenotransplanted into nude mice
112. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma
113. A phase 1 and parmacokinetic study of TNP-470 administered weekly to patients with advanced cancer
114. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix
115. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer
116. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer
117. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody
118. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
119. Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue
120. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function
121. Angiostatin suppresses malignant glioma growth in vivo
122. SU5416 is a potent selective inhibitor of the vascular endothelial growth factor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization and growth of multiple tumor types
123. Alpha-difluoromethylornithine induces apoptosis as well as anti-angiogenesis in the inhibition of tumor growth and metastasis in a human gastric cancer model